21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity
Article content
Biogen's 'Friedreich's Back' Takes Top Honors in Pharma; 21GRAMS Named No. 2 Healthcare Agency and Real Chemistry Ranked No. 2 Healthcare Network Globally on Creative Community's Biggest Stage
Article content
CANNES, France & NEW YORK — Real Chemistry continued its rise as a global creative leader in health, earning a Gold Pharma Lion at the 2025 Cannes Lions International Festival of Creativity for Biogen's 'Friedreich's Back' campaign developed by 21GRAMS, part of Real Chemistry.
Article content
'Winning at Cannes is not just about the work; it's about the willingness to push boundaries in how healthcare shows up in culture,' said Shankar Narayanan, CEO of Real Chemistry.
Further cementing its creative leadership, 21GRAMS was named the N o. 2 Healthcare Agency, and Real Chemistry was ranked the No. 2 Healthcare Network globally in the prestigious Cannes Lions Health 2025 rankings, a testament to the company's bold, data-driven storytelling and impact-driven innovation in healthcare.
Article content
'Winning at Cannes is not just about the work; it's about the willingness to push boundaries in how healthcare shows up in culture,' said Shankar Narayanan, CEO of Real Chemistry. 'These campaigns reflect our belief that creativity is a force multiplier for health outcomes when paired with science, technology and a deep understanding of humanity. We believe that healthcare deserves to be treated as inspirational and creative as any other category, and our results at Cannes prove what's possible.'
Article content
Pharma Lion Win
Article content
Gold Lion: 'Friedreich's Back' – Biogen / 21GRAMS
Friedreich's Back is a darkly funny campaign that reimagines 19th-century scientist Nikolaus Friedreich rising from the grave to make sense of a world where a treatment now exists for the disease he discovered. The campaign supported the launch the first FDA-approved treatment for Friedreich ataxia (FA), a rare, genetic and progressive disease that damages the nervous system and impacts muscle control over time.
Article content
'This win is extraordinary not just because it's a Gold Lion in Pharma, but because it's for branded work for a rare disease using comedy, which rarely breaks through in shows like these,' said Frank Mazzola, Managing Founder of 21GRAMS and Co-Global Chief Creative Officer at Real Chemistry. 'We didn't do this campaign for awards. We did it for the people who deserve to have their story told, to make a community laugh, connect and help to cope with a devastating condition. 'Friedreich's Back' proves that authentic, client-led creativity still matters – and still wins. Winning means reaching more patients and helping people. That's ultimately our purpose.'
Article content
These wins follow a year of strong creative momentum for Real Chemistry, which was named the No. 1 PR Agency by PRWeek, No. 3 in MM+M's Agency 100, and continues to expand its AI-driven storytelling and integrated intelligence platforms for pharma clients worldwide. The firm was recognized as U.S. Agency of the Year at the 2025 SABRE Awards North America and honored with Outstanding Healthcare Agency of the Year at the 2025 PRWeek US Awards. Real Chemistry was ranked as the No. 1 healthcare PR firm globally and No. 2 U.S. PR firm overall by O'Dwyer's, reflecting the agency's consistent leadership across creativity, communications and client impact.
Article content
About Real Chemistry
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
3 hours ago
- National Post
Princess of Wales pulls out of engagement at Royal Ascot
The Princess of Wales canceled plans to attend Royal Ascot on Wednesday as she continues to balance the demands of her public duties against the realities of her recovery from cancer. Article content Kate, as Prince William's wife is commonly known, has been gradually returning to public duties since last fall, when she announced that she had completed chemotherapy and would return to work. At the time, she said her road to full recovery would be long and she would 'take each day as it comes.' Article content Article content Royal Ascot, a five-day series of horse races, is the centerpiece of the summer social season in Britain, with members of the royal family attending throughout the meeting. Racegoers had hoped to see Kate on Wednesday, as Prince William was scheduled to awarding race prizes. William attended without his wife. Article content Article content
Globe and Mail
3 hours ago
- Globe and Mail
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long term are the key factors driving the increase amid several headwinds like slowing sales in the Vaccines unit, generic competition for some drugs and broader economic pressure. Let's discuss these factors in detail to understand how to play GSK's stock amid the recent price increase. GSK Specialty Medicines Unit on a Strong Footing GSK is witnessing increased sales growth of its Specialty Medicines unit, particularly reflecting successful new launches in Oncology and long-acting HIV medicines. Sales are rising in all areas, HIV, Immunology/Respiratory as well as Oncology. Sales of the Specialty Medicines unit rose 19% in 2024, driven by double-digit growth in all therapy areas. The positive trend continues in 2025 with sales rising 17% in the first quarter of 2025. In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and Apretude, as well as new oncology drugs Jemperli and Ojjaara, are also witnessing strong patient demand and contributing to top-line growth. In 2025, the company expects sales in the Specialty Medicines segment to rise in a low double-digit percentage at CER, despite the impact from the Inflation Reduction Act or IRA. Specialty Medicines, which now accounts for around 40% of GSK's sales, is expected to be more than 50% of GSK's total revenue by 2031. GSK's Promising Pipeline GSK is increasing R&D investment in promising new long-acting and specialty medicines in Respiratory, Immunology & Inflammation, Oncology and HIV areas. GSK's pentavalent MenABCWY meningococcal vaccine and Blujepa/gepotidacin for treating uncomplicated urinary tract infection ('UTI') were approved in the United States in the first quarter of 2025. Its blockbuster drug Nucala was approved for treating chronic obstructive pulmonary disease or COPD, its fifth indication, in May 2025. Regulatory applications seeking approval of the Blenrep combination for relapsed/refractory multiple myeloma and depemokimab for two indications (chronic rhinosinusitis with nasal polyps or CRSwNP and asthma with type II inflammation) are under review in the United States and some other countries. FDA decisions on all these filings are expected in 2025. Blenrep combinations were approved in the United Kingdom and Japan in April/May 2025. In 2025, GSK expects to launch five new products/line extensions, including Blenrep, depemokimab (severe asthma and CRSwNP), Nucala for COPD, Penmenvy and Blujepa. Of these, Penmenvy, Blujepa and Nucala for COPD are already approved in the United States. GSK's Vaccine Sales Slowing Down GSK's first-quarter Vaccine sales declined 6% due to lower sales of its RSV vaccine, Arexvy, and shingles vaccine, Shingrix. U.S. sales of Shingrix declined 21% in the first quarter of 2025 due to lower demand as a result of challenges in activating harder-to-reach consumers. Arexvy's global sales declined 57% in the first quarter. Revised recommendations for RSV vaccinations issued in June 2024 by the U.S. Advisory Committee on Immunization Practices (ACIP) have been hurting sales of Arexvy from the second half of 2024 in the United States. In June, the ACIP recommended the use of Arexvy for all adults aged 75 and above. However, for adults aged 60-74, the ACIP recommended the vaccine only for those who are at increased risk of severe RSV disease. A challenging macro environment in China and potential for changes in vaccination policies in the United States are expected to hurt Vaccine sales in the near term. In 2025, the company expects sales in the Vaccines segment to decline by a low single-digit percentage at CER. GSK's Price Performance, Valuation & Estimate Movement GSK stock has risen 20.1% year to date compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock has also been trading above 200 and 50-day moving averages since May. GSK Stock Outperforms Industry, Sector and S&P GSK's stock is trading at an attractive valuation relative to the industry. Going by the price/earnings ratio, the company's shares currently trade at 8.63 on a forward 12-month basis, lower than 15.63 for the industry. The stock also trades below its 5-year mean of 10.25. The stock is much cheaper than several other large drugmakers like Eli Lilly LLY, Novo Nordisk NVO, AbbVie ABBV and AstraZeneca. GSK Stock Valuation Image Source: Zacks Investment Research The Zacks Consensus Estimate for earnings has risen from $4.26 to $4.42 per share for 2025 and from $4.71 to $4.82 per share for 2026 over the past 60 days. GSK's Estimates Stay Invested in GSK Stock GSK has its share of problems. Competitive pressure on HIV and respiratory drugs has risen. The dolutegravir HIV franchise patent expires in the 2028-2029 period, and U.S. vaccine sales are slowing down. In 2025, GSK also expects a negative sales impact of £400-500 million due to the impact of the IRA Medicare Part D redesign. However, the company is consistently growing its sales and profits, mainly driven by its Specialty Medicines segment. For the five-year period till 2026, GSK expects to record more than 7% sales growth while core operating profit is expected to increase more than 11% on a CAGR basis. In this period, Specialty Medicines is expected to rise in the low-to-mid teens percentage while General Medicines is expected to rise by a low single-digit percentage. The growth in Specialty Medicines and improvement in General Medicines are making up for a slowdown in the Vaccines unit. The company also resolved the vast majority of Zantac litigations in 2024, which had long been an overhang on the stock. GSK believes it is well-positioned to navigate and mitigate the potential financial impact of tariffs on pharmaceutical imports through supply chain and increased productivity initiatives We suggest investors who own this Zacks Rank #3 (Hold) stock stay invested for now, considering steady sales and profit improvement in the coming years. Consistently rising estimates also reflect analysts' optimistic outlook for future growth in profits. Buying the stock at its present cheap valuation can prove prudent for long-term investors who are interested in buying blue-chip companies. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
CTV News
3 hours ago
- CTV News
Calgary's liveability ranking drops significantly amid health-care ‘strains': report
Calgary is no longer among the top five most liveable cities in the world according to a new report; in fact, it didn't even make the top 10. Last year, Calgary nabbed fifth spot on the Economist Intelligence Unit's (EIU) annual list. This year, Calgary saw the biggest drop in the rankings, tumbling to 18th place. The EIU, a research and analysis division of the Economist Group, released the list on Monday. It surveyed 173 cities around the world, scoring them in five categories – stability, healthcare, culture and environment, education and infrastructure – on data collected between April 14 and May 11. Copenhagen came in first place, followed by Vienna, Zurich, Melbourne and Geneva. Only four Canadian cities made the list. The one with the highest ranking was Vancouver (10), followed by Toronto (16), Calgary (18) and Montreal (19). The EUI said all the Canadian cities in the survey saw a decline in score for healthcare, as 'strains in the country's national health service intensified.'
